We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer.
- Authors
Kang, Han Na; Kim, Jae-Hwan; Park, A-Young; Choi, Jae Woo; Lim, Sun Min; Kim, Jinna; Shin, Eun Joo; Hong, Min Hee; Pyo, Kyoung-Ho; Yun, Mi Ran; Kim, Dong Hwi; Lee, Hanna; Yoon, Sun Och; Kim, Da Hee; Park, Young Min; Byeon, Hyung Kwon; Jung, Inkyung; Paik, Soonmyung; Koh, Yoon Woo; Cho, Byoung Chul
- Abstract
<bold>Background: </bold>We investigated whether head and neck squamous cell carcinoma (HNSCC) patient-derived xenografts (PDXs) reaffirm patient responses to anti-cancer therapeutics.<bold>Methods: </bold>Tumors from HNSCC patients were transplanted into immunodeficient mice and propagated via subsequent implantation. We evaluated established PDXs by histology, genomic profiling, and in vivo anti-cancer efficacy testing to confirm them as the authentic in vivo platform.<bold>Results: </bold>From 62 HNSCCs, 15 (24%) PDXs were established. The primary cancer types were tongue (8), oropharynx (3), hypopharynx (1), ethmoid sinus cancer (1), supraglottic cancer (1), and parotid gland (1); six PDXs (40%) were established from biopsy specimens from advanced HNSCC. PDXs mostly retained donor characteristics and remained stable across passages. PIK3CA (H1047R), HRAS (G12D), and TP53 mutations (H193R, I195T, R248W, R273H, E298X) and EGFR, CCND1, MYC, and PIK3CA amplifications were identified. Using the acquisition method, biopsy showed a significantly higher engraftment rate when compared with that of surgical resection (100% [6/6] vs. 16.1% [9/56], P < 0.001). Specimens obtained from metastatic sites showed a significantly higher engraftment rate than did those from primary sites (100% [9/9] vs. 11.3% [6/53], P < 0.001). Three PDX models from HPV-positive tumors were established, as compared to 12 from HPV-negative (15.8% [3/19] and 27.9% [12/43] respectively, P = 0.311), suggesting that HPV positivity tends to show a low engraftment rate. Drug responses in PDX recapitulated the clinical responses of the matching patients with pan-HER inhibitors and pan-PI3K inhibitor.<bold>Conclusions: </bold>Genetically and clinically annotated HNSCC PDXs could be useful preclinical tools for evaluating biomarkers, therapeutic targets, and new drug discovery.
- Subjects
HEAD &; neck cancer; SURGICAL excision; SQUAMOUS cell carcinoma; PAROTID glands; TONGUE cancer; THERAPEUTICS
- Publication
BMC Cancer, 2020, Vol 20, Issue 1, p1
- ISSN
1471-2407
- Publication type
journal article
- DOI
10.1186/s12885-020-06786-5